ArticleFrontiers in cardiovascular medicine2025
Burden of non-rheumatic valvular heart disease globally and in China from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-rheumatic valvular heart disease (NRVHD), driven by aging populations and epidemiological transitions, has become the dominant form of valvular heart disease globally, yet its burden trends and demographic disparities remain undercharacterized. This study quantifies the global and Chinese burden of NRVHD from 1990 to 2021, analyzing age-sex disparities and temporal trends. Methods: Using data from the Global Burden of Disease (GBD) 2021 Study. First, the number of incidence, prevalence, deaths, and disability-adjusted life years (DALYs) cases, along with their corresponding age-standardized rates (ASRs), were reported globally and in China, stratified by different sub-types in 2021. These sub-types included sex and age groups. Second, to explore the temporal trend of the disease burden, data from 1990 to 2021 were analyzed both globally and by sub-types. The estimated annual percentage change (EAPC) value was calculated using a linear regression model. Results: In 2021, NRVHD caused 2,206,928 global incidence cases (ASR: 25.0/100,000) and 28.4 million prevalence cases (ASR: 335.3/100,000), with 181,078 deaths (ASR: 2.31/100,000) and 3.24 million DALYs (ASR: 39.7/100,000). China accounted for 292,215 incidence cases (ASR: 12.8/100,000) and 3.28 million prevalence cases (ASR: 156.2/100,000), demonstrating lower deaths cases (ASDR: 0.13 vs. global 2.31/100,000) but accelerated burden growth. From 1990 to 2021, global incidence rose 129%, while China's surged 220%. Age-standardized deaths rate declined globally and in China, contrasting with rising prevalence. Males bore higher burdens globally and in China, with elderly populations disproportionately affected. Conclusion: NRVHD burden has escalated globally, characterized by rising morbidity amid declining mortality, a paradox amplified in China. While therapeutic advances and hypertension control contributed to mortality reductions, persistent sex-age disparities and rural-urban inequities demand targeted strategies. China's rapid epidemiological transition underscores the urgency of integrating primary prevention, equitable technology access, and enhanced surveillance to address aging-related valvulopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.